LEVOSAH - Pilot study comparing the effectiveness of adding treatment with Levosimendan to usual care for the management of the acute phase of aneurysmal subarachnoid hemorrhages

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514242-36-00

Acronym

APHP200175

Enrollment

Registered

2024-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subarachnoid hemorrhages of aneurysmal origin (HSAa)

Brief summary

the occurrence of cerebral arterial vasospasm within 14 days of the bleeding

Detailed description

the cumulative incidence of death rate, ICDs and vasospasms, The mRS score at 6 months, Impact of Levosimendan treatment on cardiac dysfunction

Interventions

DRUGGLUCOSE 5 % B.BRAUN

DRUGsolution pour perfusion

DRUGZIMINO 2

DRUG5 mg/ml

DRUGsolution à diluer pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the occurrence of cerebral arterial vasospasm within 14 days of the bleeding	—

Secondary

Measure	Time frame
the cumulative incidence of death rate, ICDs and vasospasms, The mRS score at 6 months, Impact of Levosimendan treatment on cardiac dysfunction	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026